Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, November 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 88 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications

Article in The Chemical Record (November 2023)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Article in Health Economics Review (November 2023)

Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?

Article in Expert Review of Pharmacoeconomics & Outcomes Research (September 2023)